Reply to Olle et al. - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Reply to Olle et al.

  • By

  • Brendan J Kelly

  • Jennie H Kwon

  • Michael H Woodworth

  • November 19, 2024

Share

  • 1

    The authors express gratitude to Olle et al for clarifying terminology in microbiome-based therapeutics.

  • 2

    Clear terminology is essential for clinicians to differentiate between fecal microbiota products and live biotherapeutic products.

  • 3

    The field of microbiome-based therapeutics is rapidly evolving, necessitating precise definitions.

  • 4

    Fecal microbiota products and live biotherapeutic products may improve treatment for Clostridioides difficile infections.

  • 5

    The authors believe these therapies will benefit both patients and researchers studying their mechanisms.

Original Source(s)

Reply to Olle et al.

  • by Brendan J Kelly, Jennie H Kwon, Michael H Woodworth

  • November 19, 2024

Related Content

Microsporidial keratoconjunctivitis may mimic allergy

Molecular testing identified Encephalitozoon hellem in a 9-year-old orthokeratology lens wearer after conventional treatment failed.

Antibiotics May Not Help Mild COVID

A retrospective cohort study of more than 520,000 hospitalized patients found no clinically meaningful improvement in deterioration or mortality with early treatment targeting community-acquired pneumonia.

How does IBD relate to joint infection risk?

Investigators assessed 90-day outcomes among patients with IBD who underwent elective total joint arthroplasty.